Tela Bio, Inc. insider trading
Every open-market purchase and sale by Tela Bio, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Tela Bio, Inc.’s insiders pay?
From December 17, 2019 to September 18, 2026, 13 insiders reported 89 open-market purchases and 3 sales not made under a pre-set plan in Tela Bio, Inc. Twelve months after each purchase was reported, the shares were −0.9% against the S&P 500 on average (median +1.5%), over 79 purchases with a full year of prices; 56% beat the index. After sales, the shares moved −33.4% against the index over 12 months (a negative figure means selling was the right call). Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on December 18, 2019 into $1,905 by November 2, 2026, −21.5% a year. It held shares 57% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $16,984 (+8.0% a year), and held throughout $26,161 (+15.1%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Ew Healthcare Partners Fund 2 Gp, L.P. | 10% owner | 17 | −14.9% (17) | 41% | 0 | — | February 16, 2024 |
| Opaleye Management Inc. | 10% owner | 16 | −0.7% (16) | 56% | 0 | — | November 4, 2022 |
| Ew Healthcare Partners Fund 2, L.P. | 10% owner | 14 | +3.3% (14) | 64% | 0 | — | June 10, 2022 |
| Ew Healthcare Partners Fund 2-A, L.P. | 10% owner | 14 | +2.9% (14) | 50% | 0 | — | June 24, 2022 |
| Ew Healthcare Partners Fund 2-Ugp, LLC | 10% owner | 14 | +9.6% (13) | 77% | 0 | — | November 17, 2025 |
| Cuca Roberto | COO and CFO | 5 | +12.9% (3) | 33% | 0 | — | October 24, 2024 |
| Capper Joseph H | Director | 2 | — | — | 0 | — | September 18, 2026 |
| Firestone Gregory A. | Chief Commercial Officer | 2 | −79.2% (1) | 0% | 0 | — | October 24, 2024 |
| Koblish Antony | Chief Executive Officer | 2 | — | — | 0 | — | October 24, 2024 |
| Orbimed Advisors LLC | 10% owner | 0 | — | — | 2 | −77.2% (1) | July 2, 2024 |
| Wong Roderick | 10% owner | 1 | +21.4% (1) | 100% | 1 | +10.4% (1) | December 18, 2019 |
| Getz Heather C | Chief Executive Officer | 1 | — | — | 0 | — | August 17, 2026 |
| Talmo Paul | Chief Technology Officer | 1 | — | — | 0 | — | October 24, 2024 |
When several insiders traded Tela Bio, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Tela Bio, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 3 buying crowds with six months of prices, it averaged −17.6% against the index. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| November 30, 2023 | 2 buying | +20.5% | −10.9% | −76.7% |
| September 30, 2021 | 3 buying | −21.9% | −20.8% | −22.1% |
| May 28, 2021 | 4 buying | −10.3% | −21.0% | −46.6% |